Crinetics Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Checking your notes…
(in thousands)
| Six months ended | ||
|---|---|---|
| June 30, | ||
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(248,700) | $(212,411) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 54,561 | 46,602 |
| Depreciation and amortization | 2,233 | 1,884 |
| Noncash lease expense | 1,386 | 1,605 |
| Accretion of purchase discounts and amortization of premiums on investment securities, net | (4,243) | (9,090) |
| Loss on disposal of property and equipment | 20 | 42 |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | (11,365) | — |
| Inventory | (1,267) | — |
| Prepaid expenses and other assets | (7,487) | (11,325) |
| Accounts payable and accrued expenses, compensation and related expenses, and other liabilities | (2,772) | 11,160 |
| Deferred revenue | 88 | (984) |
| Operating lease liabilities | (1,350) | (1,786) |
| Net cash used in operating activities | (218,896) | (174,303) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of investment securities | (709,639) | (574,081) |
| Proceeds from sales and maturities of investment securities | 484,914 | 530,514 |
| Purchases of property and equipment | (1,341) | (4,441) |
| Net cash used in investing activities | (226,066) | (48,008) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common stock, net of commissions | 380,514 | — |
| Offering costs related to issuance of common stock | (578) | — |
| Proceeds from exercise of stock options and shares issued under ESPP | 18,864 | 11,492 |
| Net cash provided by financing activities | 398,800 | 11,492 |
| Net change in cash, cash equivalents and restricted cash | (46,162) | (210,819) |
| Exchange rate changes in cash, cash equivalents and restricted cash | 124 | — |
| Cash, cash equivalents and restricted cash - beginning of period | 102,336 | 265,845 |
| Cash, cash equivalents and restricted cash - end of period | $56,298 | $55,026 |
| COMPONENTS OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH | ||
| Cash and cash equivalents | $55,498 | $53,726 |
| Restricted cash | 800 | 1,300 |
| Cash, cash equivalents and restricted cash at end of period | $56,298 | $55,026 |
| NONCASH INVESTING AND FINANCING ACTIVITIES | ||
| Stock options exercised receivable | $56 | $369 |
| Amounts accrued for purchases of property and equipment | $358 | $87 |
| Amounts accrued for offering costs | $165 | $— |
| Stock held in trust | $1,151 | $112 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.